NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000108

Registered date:02/09/2005

A randomized phase II/III study of ACNU versus Procarbazine plus ACNU as a postoperative chemoradiotherapy for strocytoma grade 3 and 4(JCOG0305, ACNU+PCZ PhaseII/III)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedastrocytoma grade 3/4
Date of first enrollment2004/06/01
Target sample size310
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)A: RT+ACNU B: RT+Procarbazine+ACNU

Outcome(s)

Primary OutcomeEndpoint in phase II stage: 6 months survival Endpoint in phase III stage: Overall survival (OS)
Secondary OutcomeEndpoint in phase II stage: Overall survival (OS) Endpoint in phase III stage: Progression free survival (PFS) ,Response rate (RR), % complete response (%CR),Toxicity

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum69years-old
GenderMale and Female
Include criteria
Exclude criteria1. Synchronous double cancer or metachronous double cancer in last 5 years; carcinoma in situ accepted 2. Meningitis or pneumonia 3. Pregnant, possibly pregnant or nursing women 4. Mental disorder 5. Uncontrollable diabetes mellitus or DM under treatment with Insulin 6. Myocardial infarction in last 3 months 7. History of pulmonary fibrosis or interstitial pneumonia

Related Information

Contact

public contact
Name Soichiro Shibui, MD, DMSc
Address 5-1-1 Tukiji, Chuo-ku, Tokyo, 104-0045, Japan Japan
Telephone
E-mail JCOG_sir@ml.jcog.jp
Affiliation JCOG0305 Coordinating Office Neurosurgery Division, National Cancer Center Hospital
scientific contact
Name Soichiro Shibui, MD, DMSc
Address 5-1-1 Tukiji, Chuo-ku, Tokyo, 104-0045, Japan Japan
Telephone
E-mail
Affiliation National Cancer Center Hospital Neurosurgery Division